Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.
The move brings the total investment in Central Ohio to more than $1.4bn, and the total number of national employment opportunities created to 750.
Go deeper with GlobalData
The expansion is part of the company’s strategy to enhance its manufacturing offerings in the US.
It first established its presence in the Ohio region in June 2021 with the announcement of a biomanufacturing facility in the Columbus Region, generating 400 employment opportunities.
In February 2024, the company opened the 300,000 ft² Ohio facility to meet the growing demand for its medications within the country.
Following the Tax Cuts and Jobs Act of 2017, Amgen has made substantial investments in the US.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt has invested almost $5bn in direct capital expenditures, contributing an additional $12bn in downstream output to the country’s economy.
The Ohio expansion is part of Amgen’s worldwide biomanufacturing network, which benefits from operational expertise and technological advancements.
The investments across the US align with the company’s focus on establishing biologics manufacturing capabilities globally.
Amgen CEO and chairman Robert Bradway stated: “Today’s investment reinforces our ongoing commitment to expanding US manufacturing and ensuring patients around the world have access to our innovative medicines.
“Ohio offers a supportive business climate, skilled workforce and strategic location, making it an ideal choice for this next phase of our investment.”
In January 2025, Amgen inaugurated a new drug substance facility in the US after announcing a further $1bn expansion at its North Carolina site.
